---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-089234"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:35:54.416191+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cerus Q2 product revenue up 16% to $45M; raises FY2024 guidance to $175-178M

## Summary
- Q2 product revenue $45.1M (+16% YoY); total revenue $50.5M (+6% YoY).
- GAAP net loss narrowed to $5.8M ($0.03/share) from $13.3M loss in Q2 2023.
- Non-GAAP adjusted EBITDA turned positive at $0.8M (vs -$4.7M prior year).
- Full-year product revenue guidance raised to $175-178M; IFC guidance unchanged at $8-10M.
- Canadian Blood Services achieved 100% INTERCEPT platelet adoption.

## SEC filing metadata
- accession: 0000950170-24-089234
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000095017024089234/0000950170-24-089234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000095017024089234/cers-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-089234
- JSON: https://secwatch.observer/filing/0000950170-24-089234.json
- Plain text: https://secwatch.observer/filing/0000950170-24-089234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.